MBK-001 is under clinical development by Mikrobiomik Healthcare Company and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MBK-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MBK-001 overview
MBK-001 is under development for the treatment of recurrent Clostridioides difficile infections, non-alcoholic steatohepatitis (NASH), metastatic colorectal, metastatic pancreatic and gastric cancer. It is administered through oral route as capsule. It comprises of fecal microbiota and is developed based on Total Fecal Microbiota (TFM) technology.
The drug candidate was also under development for the treatment of carbapenemase-producing Klebsiella pneumoniae (KPC) infection.
Mikrobiomik Healthcare Company overview
Mikrobiomik is a biopharmaceutical company, born to research, develop, and market medicines based on human microbiota, providing innovative solutions in chronic diseases. It is headquartered in Euskadi, Spain.
For a complete picture of MBK-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
